Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy
NCT00566852Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Mar 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of memantine in cognitive dysfunction, sponsored by NRG Oncology. Started Mar 2008; status: completed.
02
Drugs
memantine
03
Conditions
cognitive dysfunction
Beyond the preview
Go deeper on NCT00566852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566852.